Postmarketing reports of product-related insertional oncogenesis involving GLI1 have prompted an FDA investigation into malignancy risk with SMA gene therapy, onasemnogene abeparvovec.
|Slideshows|August 30, 2018
Occupational Exposures and Risk of ALS
Author(s)Veronica Hackethal, MD
If your patient is a construction worker, bus driver, gas station attendant, or mechanic, take notice: “This type of exposure deserves more attention and study as we work to develop a better understanding of what causes ALS,” notes the author of a recent study.
Advertisement
Advertisement
Related to this article
Interim phase 1b data showed cizutamig produced rapid, sustained improvement in generalized myasthenia gravis with no cases of cytokine release syndrome.
Catch up on any of the neurology headlines you may have missed in October 2026, compiled into 1 place by the NeurologyLive® team.
Here's some of what is coming soon to NeurologyLive® this week.
Newly presented biomarker and clinical findings from the phase 2b PARADIGM trial of PrimeC informed the design of the global phase 3 PARAGON trial in ALS.
Two-year data from the phase 2 DAZALS trial showed a lower risk of death with dazucorilant 300 mg/day vs placebo in ALS, although the study did not meet its functional primary end point.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 6, 2026.
Servier reported that sevasemten did not meet its primary or secondary endpoints in the pivotal GRAND CANYON trial for Becker muscular dystrophy.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Factor XIa Inhibitor Asundexian for Secondary Stroke Prevention
2
FDA Investigates Confirmed Insertional Oncogenesis With Spinal Muscular Atrophy Gene Therapy
3
Examining High-Dose Influenza Vaccination and Alzheimer Disease Risk
4
Identifying the Biggest Neuromuscular Advocacy Challenges for 2027: Paul Melmeyer, MPP
5